Mini-review: Antibody-PET of receptor tyrosine kinase interplay and heterogeneity
A Chegu, SS Panikar, PMR Pereira - Nuclear Medicine and Biology, 2022 - Elsevier
Targeted tumor therapies of receptor tyrosine kinases (RTK) do not work for every patient
with cancer, owing to differences in the level of RTK heterogeneity, RTK co-activation …
with cancer, owing to differences in the level of RTK heterogeneity, RTK co-activation …
Mini-review: Antibody-PET of receptor tyrosine kinase interplay and heterogeneity.
A Chegu, SS Panikar, PMR Pereira - Nuclear Medicine and Biology, 2022 - europepmc.org
Targeted tumor therapies of receptor tyrosine kinases (RTK) do not work for every patient
with cancer, owing to differences in the level of RTK heterogeneity, RTK co-activation …
with cancer, owing to differences in the level of RTK heterogeneity, RTK co-activation …
Mini-review: Antibody-PET of receptor tyrosine kinase interplay and heterogeneity
A Chegu, SS Panikar, PMR Pereira - Nuclear Medicine and …, 2022 - profiles.wustl.edu
Targeted tumor therapies of receptor tyrosine kinases (RTK) do not work for every patient
with cancer, owing to differences in the level of RTK heterogeneity, RTK co-activation …
with cancer, owing to differences in the level of RTK heterogeneity, RTK co-activation …
Mini-review: Antibody-PET of receptor tyrosine kinase interplay and heterogeneity
A Chegu, SS Panikar… - Nuclear medicine and …, 2022 - pubmed.ncbi.nlm.nih.gov
Targeted tumor therapies of receptor tyrosine kinases (RTK) do not work for every patient
with cancer, owing to differences in the level of RTK heterogeneity, RTK co-activation …
with cancer, owing to differences in the level of RTK heterogeneity, RTK co-activation …